Top Page
Memphasys Ltd
(Sydney:MEM)
Memphasys Ltd (MEM) vs. iShares MSCI Australia ETF (EWA)
Memphasys Ltd Business Overview & Revenue Model
Memphasys Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 526.92K | 526.92K | 60.00K | 15.37K | 27.15K | 211.48K |
| Gross Profit | 431.06K | 431.06K | -1.57M | -824.86K | -922.60K | -48.00K |
| EBITDA | -2.57M | -2.57M | -4.24M | -2.36M | -1.39M | -1.14M |
| Net Income | -4.94M | -4.94M | -4.44M | -3.40M | -2.08M | -1.49M |
Balance Sheet | ||||||
| Total Assets | 11.02M | 11.02M | 12.43M | 14.67M | 14.12M | 14.58M |
| Cash, Cash Equivalents and Short-Term Investments | 298.30K | 298.30K | 277.80K | 637.83K | 311.83K | 2.00M |
| Total Debt | 5.11M | 5.11M | 4.81M | 6.37M | 5.56M | 5.36M |
| Total Liabilities | 5.65M | 5.65M | 5.59M | 7.28M | 6.47M | 5.97M |
| Stockholders Equity | 5.37M | 5.37M | 6.84M | 7.38M | 7.65M | 8.61M |
Cash Flow | ||||||
| Free Cash Flow | -2.41M | -2.41M | -3.87M | -3.23M | -2.61M | -2.96M |
| Operating Cash Flow | -2.41M | -2.41M | -3.23M | -1.41M | 311.82K | 47.25K |
| Investing Cash Flow | -673.28K | -673.28K | -711.05K | -1.98M | -3.08M | -3.00M |
| Financing Cash Flow | 3.15M | 3.15M | 3.54M | 3.75M | 1.03M | 2.99M |
Memphasys Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$36.73M | -9.09 | -143.71% | ― | 306.88% | ― | |
42 Neutral | AU$14.57M | -1.69 | -469.35% | ― | ― | 46.28% | |
39 Underperform | AU$10.46M | -3.57 | -90.15% | ― | -93.83% | 20.00% | |
37 Underperform | AU$6.89M | -1.61 | -628.72% | ― | ― | 31.87% |
Memphasys Ltd Corporate Events
Memphasys Ltd announced the results of its Annual General Meeting held on November 20, 2025. Several resolutions were passed, including the election of directors and the approval of issuing shares and options to various stakeholders. The outcomes of these resolutions are expected to influence the company’s strategic direction and stakeholder engagement, reflecting a focus on strengthening its governance and financial structure.
Memphasys Ltd, a company listed on the Australian Securities Exchange (ASX) under the ticker MEM, is focused on the commercialisation of its product, Felix. The company has released an investor presentation outlining its strategic focus on product development and commercialisation activities, with indicative timelines subject to change. This announcement highlights Memphasys’s commitment to advancing its market presence and operational capabilities, potentially impacting its industry positioning and stakeholder interests.
Memphasys Limited has undergone significant strategic realignment, focusing on the commercial success of its Felix™ system. The company has shifted from a traditional distributor model to engaging with partners for better market adoption and has implemented cost-saving measures to improve operational efficiency. Key achievements include securing initial orders from international partners and progressing towards CE Mark regulatory approval, expected in early 2026. These efforts have strengthened Memphasys’ governance and commercial pathways, positioning it as a leading fertility technology company.
Memphasys Limited has issued 33,333,333 fully paid ordinary shares at $0.003 per share to professional and sophisticated investors, as part of a placement announced in September 2025. This move is in line with the company’s strategy to scale production and establish the Felix ™ System as a global standard in sperm preparation for IVF, potentially enhancing its market position and operational efficiency.
Memphasys Limited has announced the application for the quotation of 33,333,333 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction, and it signifies a strategic step in enhancing the company’s market presence and liquidity, potentially impacting its stakeholders by increasing the accessibility and tradability of its shares.
Memphasys Ltd has announced the issuance of 45,115,338 unquoted securities, specifically options expiring on November 5, 2026. This move is part of previously announced transactions and is not intended to be quoted on the ASX, potentially impacting the company’s financial strategy and stakeholder interests.
Memphasys Ltd has announced the quotation of 180,460,810 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of November 10, 2025. This move is part of a previously announced transaction and is expected to enhance the company’s market presence and liquidity, potentially benefiting stakeholders by increasing the company’s financial flexibility and visibility in the market.
Memphasys Limited has successfully completed its Entitlement Offer, raising approximately $541,382.43 through the issuance of new shares and options. The funds will be used to advance the commercialization of the Felix™ System, including obtaining CE Mark approval for entry into European markets, scaling up manufacturing, and implementing marketing strategies in key regions. This financial move is expected to bolster Memphasys’s market positioning and facilitate the transition to recurring revenues, benefiting stakeholders by enhancing the company’s operational capabilities and market reach.
Memphasys Limited has completed a strategic shift to focus exclusively on the commercialisation of its Felix™ System, marking a transition from R&D to commercial execution. The company has achieved significant milestones, including a five-year distribution agreement in the MENA region, operational cost reductions, and strengthened governance, positioning itself for sustainable growth and increased market presence.
Memphasys Limited has signed a non-exclusive supply agreement with Andrology Center Coimbatore to expand its Felix™ System’s presence in the Indian market. This agreement marks a strategic shift to a go-direct commercial strategy, aiming to accelerate product adoption across over 200 IVF clinics in India. The partnership is expected to drive significant growth for Memphasys, with a minimum commitment of 1,800 Felix™ cartridges in the first year and a 50% increase in the second year. This move re-establishes Memphasys’ presence in India following regulatory changes and positions the company to capitalize on the rapidly expanding Indian IVF market, which is projected to grow significantly in the coming years.
Memphasys Limited announced changes in its board of directors, with Mr. Mathew Watkins appointed and Mr. David Ali ceasing as directors. The company acknowledged an administrative oversight in the timely filing of director interest notices but assured that current compliance arrangements are adequate. These changes are not expected to impact the company’s operations or compliance with ASX listing rules.
Memphasys Limited has secured a repeat order for 200 Felix ™ cartridges from the Nishitan ART Clinic Group in Japan, highlighting the growing adoption of its technology in the world’s largest IVF market. This order marks a significant step in Memphasys’ strategy to expand its direct commercial footprint in Japan, leveraging the country’s substantial self-pay IVF segment to drive revenue growth and enhance its market position.
Memphasys Ltd has announced the details for its 2025 Annual General Meeting (AGM), which will be held physically in Sydney. The company is adapting to modern communication methods by providing meeting materials online and encouraging electronic voting and communication, reflecting a shift towards more digital engagement with shareholders.
Memphasys Limited has announced several board changes as it pivots towards the commercialisation of its Felix ™ System. Dr. David Ali will step down as Executive Director to focus on his role as CEO, emphasizing operational execution as the company prepares for a global market rollout. Marjan Mikel has been appointed Chair of Commercialisation to oversee strategy and market expansion, while Mathew Watkins joins as an Independent Non-Executive Director, bringing extensive ASX experience to support the company’s growth and compliance efforts. These changes are aimed at strengthening Memphasys’ ability to execute its commercialisation plan, including the European launch post CE-Mark approval.
Memphasys Limited has dispatched its prospectus for a 1-for-6 pro-rata Non-Renounceable Entitlement Issue, aiming to raise approximately $1.12 million. The funds will support the commercialisation of the Felix™ System, including regulatory approvals for the European market, and provide working capital for corporate purposes. This initiative is expected to enhance Memphasys’s market position in the fertility treatment industry by advancing the adoption and production of its Felix™ System.
Memphasys Limited has announced a change in its company secretary, with Mr. Andrew Metcalfe concluding his role and Mr. Stefan Ross stepping in as the new Company Secretary effective 8 October 2025. Mr. Ross brings over 17 years of experience in governance and compliance, which will be instrumental as Memphasys progresses the commercialisation of its Felix™ System, aiming to establish it as a global standard in sperm selection.
Memphasys Ltd has announced an update regarding the proposed issue of securities, specifically a new class of options that will be unquoted. This update is part of their ongoing efforts to manage securities and align with ASX Listing Rules, potentially impacting their market operations and investor relations.
Memphasys Ltd has announced a proposed issue of securities, with a total of 118,564,120 securities to be issued, including various options and ordinary fully paid shares. This strategic move is expected to enhance the company’s capital structure, potentially impacting its market positioning and providing opportunities for growth and expansion in the reproductive biotechnology industry.
Memphasys Ltd has announced a proposed issue of securities, including 93,379,088 NRRI options and 373,516,350 ordinary fully paid shares, as part of a standard pro rata issue. This move is expected to impact the company’s financial structure and may influence its market positioning by potentially increasing capital for further development and expansion, thereby affecting stakeholders’ interests.
Memphasys Ltd has announced a pro-rata non-renounceable entitlement offer, allowing shareholders to acquire 1 share for every 6 shares held at $0.003 per share, along with 1 free new option for every 4 shares applied for. The company aims to raise approximately $1,120,549 through this offer, which includes secondary offers of new options to placement participants and Lynx. This move is part of Memphasys’ strategy to strengthen its financial position and potentially enhance shareholder value, although the securities offered are considered highly speculative.
Memphasys Limited has completed a placement of 257,500,000 ordinary shares at $0.003 per share, as announced on 1 October 2025. The company has issued these shares without disclosure under Part 6D.2 of the Corporations Act and has confirmed compliance with relevant provisions of the Corporations Act, ensuring transparency and adherence to regulatory standards.
Memphasys Ltd announced the application for quotation of 257,500,000 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of previously announced transactions and is expected to impact the company’s market presence by potentially increasing liquidity and investor interest.
Memphasys Ltd, a company listed on the Australian Securities Exchange (ASX), has released an investor presentation focused on the commercialization of its product, Felix. The presentation outlines indicative timelines for product development and commercialization activities, emphasizing that these timelines are based on current estimates and may change. The company advises investors to seek appropriate financial advice before making any investment decisions and disclaims any responsibility for the information provided in the presentation.
Memphasys Ltd has announced a proposed issue of securities, planning to issue up to 297,500,000 ordinary fully paid shares and 74,375,000 placement options. This move is aimed at raising capital to support the company’s operations and strategic initiatives, potentially enhancing its market position and providing value to stakeholders.
Memphasys Limited has successfully completed a placement raising approximately $0.84 million to accelerate the commercialisation and manufacturing scale-up of its Felix™ technology. The company has also reduced its operational costs by 40%, redirecting funds towards manufacturing and inventory build-up to improve gross margins. This strategic pivot has garnered strong investor support, emphasizing the company’s focus on immediate revenue generation and cost efficiency. The raised funds will be used to fulfill existing contracts, progress negotiations in new markets, and support regulatory processes, positioning Memphasys for significant revenue growth in FY2026.
Memphasys Limited, listed on the Australian Securities Exchange under the code MEM, has requested a trading halt pending an announcement regarding a proposed capital raising. The halt is intended to ensure an orderly market in the company’s securities. The trading halt is expected to last until Memphasys makes the announcement, anticipated before the commencement of trading on Monday, 22 September 2025.
Memphasys Limited has announced a significant upgrade to its contract with International Technical Legacy (ITL), increasing the contract value to A$390,000 and expanding its territory to include Turkey, a key IVF market in the EU. This expansion marks Memphasys’ first contracted revenues in the EU, contingent on CE Mark approval, and is part of a broader strategy to establish a scalable revenue model and strengthen its presence in the European IVF market.
Memphasys Limited announced the resignation of Mr. Paul Wright as Non-Executive Director, who has been with the company since March 2020, contributing significantly to its progress. The company remains focused on the commercialisation of its Felix™ technology in early access markets, supported by a strong board with expertise in technology, commercialisation, and reproductive health, ensuring continued growth and strategic development.
Memphasys Limited has signed a transformative five-year exclusive distribution agreement with International Technical Legacy (ITL) for its Felix™ sperm preparation system across 15 countries in the Middle East and North Africa. This partnership, which includes an initial order valued at A$325,000 contingent on CE Mark approval, positions Memphasys to access a market with approximately 140,000 IVF cycles annually. The agreement ensures rapid adoption through ITL’s established presence and expertise, and it includes provisions for future reproductive technologies. Memphasys is also pursuing similar agreements in other regions, aiming to generate immediate cash flows and diversify revenue streams, thereby de-risking its broader rollout strategy.